Irritable bowel syndrome: New insights into symptom mechanisms and advances in treatment.

F1000Research

Volumn 5, Issue , 2016, Pages

  Spiller, Robin ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; BILE ACID; BIOLOGICAL MARKER; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; NEUROMODULIN; ONDANSETRON; OPIATE; RAMOSETRON; SEROTONIN TRANSPORTER; VANILLOID RECEPTOR 1;

ABDOMINAL DISCOMFORT; ABDOMINAL RADIOGRAPHY; BLOATING; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; FLATULENCE; HUMAN; INTESTINE FLORA; IRRITABLE COLON; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; REMISSION; REVIEW; SYMPTOM;

EID: 85010874818     PISSN: None     EISSN: 20461402     Source Type: Journal    
DOI: 10.12688/F1000RESEARCH.7992.1     Document Type: Review

References (73)

1. Wedlake L, A'Hern R, Russell D, et al.: Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009; 30(7): 707-717.
2. Aziz I, Mumtaz S, Bholah H, et al.: High Prevalence of Idiopathic Bile Acid Diarrhea Among Patients With Diarrhea-predominant Irritable Bowel Syndrome Based on Rome III Criteria. Clin Gastroenterol Hepatol. 2015; 13(9): 1650-5.e2.
3. Williams AJ, Merrick MV, Eastwood MA: Idiopathic bile acid malabsorption-a review of clinical presentation, diagnosis, and response to treatment. Gut. 1991; 32(9): 1004-1006.
4. Pattni SS, Brydon WG, Dew T, et al.: Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharmacol Ther. 2013; 38(8): 967-976.
5. Sinha L, Liston R, Testa HJ, et al.: Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther. 1998; 12(9): 839-844.
6. Chey WD, Camilleri M, Chang L, et al.: A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation. Am J Gastroenterol. 2011; 106(10): 1803-1812.
7. Simrén M, Bajor A, Gillberg PG, et al.: Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation-a double-blind study. Aliment Pharmacol Ther. 2011; 34(1): 41-50.
8. Camilleri M, Vazquez-Roque MI, Carlson P, et al.: Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterol Motil. 2011; 23(11): 995-9, e458.
9. Camilleri M, Shin A, Busciglio I, et al.: Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. Am J Physiol Gastrointest Liver Physiol. 2014; 307(5): G508-G516.
10. Halpin SJ, Ford AC: Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and metaanalysis. Am J Gastroenterol. 2012; 107(10): 1474-1482.
11. Spiller R, Lam C: The shifting interface between IBS and IBD. Curr Opin Pharmacol. 2011; 11(6): 586-592.
12. Keohane J, O'Mahony C, O'Mahony L, et al.: Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010; 105(8): 1788, 1789-94; quiz 1795.
13. Berrill JW, Green JT, Hood K, et al.: Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. Aliment Pharmacol Ther. 2013; 38(1): 44-51.
14. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, et al.: Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014; 63(5): 744-752.
15. Akbar A, Yiangou Y, Facer P, et al.: Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut. 2008; 57(7): 923-929.
16. Jones RC 3rd, Otsuka E, Wagstrom E, et al.: Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouse. Gastroenterology. 2007; 133(1): 184-194.
17. Akbar A, Yiangou Y, Facer P, et al.: Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut. 2010; 59(6): 767-774.
18. Barbara G, Stanghellini V, De Giorgio R, et al.: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004; 126(3): 693-702.
19. Dothel G, Barbaro MR, Boudin H, et al.: Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2015; 148(5): 1002-1011.e4.
20. Bellini M, Rappelli L, Blandizzi C, et al.: Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol. 2003; 98(12): 2705-2711.
21. Foley S, Garsed K, Singh G, et al.: Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology. 2011; 140(5): 1434-43.e1.
22. Coates MD, Mahoney CR, Linden DR, et al.: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 2004; 126(7): 1657-1664.
23. Kerckhoffs AP, ter Linde JJ, Akkermans LM, et al.: SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine. Am J Physiol Gastrointest Liver Physiol. 2012; 302(9): G1053-G1060.
24. Camilleri M, Andrews CN, Bharucha AE, et al.: Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology. 2007; 132(1): 17-25.
25. Wang YM, Chang Y, Chang YY, et al.: Serotonin transporter gene promoter region polymorphisms and serotonin transporter expression in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol Motil. 2012; 24(6): 560-565, e254-5.
26. Shiotani A, Kusunoki H, Ishii M, et al.: Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1. Neurogastroenterol Motil. 2015; 27(1): 82-91.
27. Camilleri M, Atanasova E, Carlson PJ, et al.: Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2002; 123(2): 425-432.
28. Garsed K, Chernova J, Hastings M, et al.: A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014; 63(10): 1617-1625.
29. Khalaf A, Hoad CL, Spiller RC, et al.: Magnetic resonance imaging biomarkers of gastrointestinal motor function and fluid distribution. World J Gastrointest Pathophysiol. 2015; 6(4): 140-149.
30. Marciani L, Cox EF, Hoad CL, et al.: Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome. Gastroenterology. 2010; 138(2): 469-77, 477.e1.
31. Marciani L, Wright J, Foley S, et al.: Effects of a 5-HT3 antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2010; 32(5): 655-663.
32. Murray K, Wilkinson-Smith V, Hoad C, et al.: Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol. 2014; 109(1): 110-119.
33. Hussein MO, Hoad CL, Wright J, et al.: Fat emulsion intragastric stability and droplet size modulate gastrointestinal responses and subsequent food intake in young adults. J Nutr. 2015; 145(6): 1170-1177.
34. Lam C, Chaddock G, Marciani L, et al.: Colonic response to laxative ingestion as assessed by MRI differs in constipated irritable bowel syndrome compared to functional constipation. Neurogastroenterol Motil. 2016.
35. Nanda R, James R, Smith H, et al.: Food intolerance and the irritable bowel syndrome. Gut. 1989; 30(8): 1099-1104.
36. Parker TJ, Naylor SJ, Riordan AM, et al.: Management of patients with food intolerance in irritable bowel syndrome: The development and use of an exclusion diet. J Human Nutrition Dietetics. 1995; 8(3): 159-166.
37. Halmos EP, Power VA, Shepherd SJ, et al.: A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014; 146(1): 67-75.e5.
38. Bohn L, Storsrud S, Liljebo T, et al.: Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015; 149(6): 1399-1407.e2.
39. Pohl D, Savarino E, Hersberger M, et al.: Excellent agreement between genetic and hydrogen breath tests for lactase deficiency and the role of extended symptom assessment. Br J Nutr. 2010; 104(6): 900-907.
40. Simrén M, Barbara G, Flint HJ, et al.: Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013; 62(1): 159-176.
41. Rajilic-Stojanovic M, Jonkers DM, Salonen A, et al.: Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol. 2015; 110(2): 278-287.
42. Vandeputte D, Falony G, Vieira-Silva S, et al.: Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016; 65(1): 57-62.
43. Pimentel M, Hwang L, Melmed GY, et al.: New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. Dig Dis Sci. 2010; 55(1): 145-149.
44. Jeffery IB, O'Toole PW, Ohman L, et al.: An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012; 61(7): 997-1006.
45. Jalanka-Tuovinen J, Salojarvi J, Salonen A, et al.: Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014; 63(11): 1737-1745.
46. Posserud I, Stotzer PO, Bjornsson ES, et al.: Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007; 56(6): 802-808.
47. Christl SU, Murgatroyd PR, Gibson GR, et al.: Production, metabolism, and excretion of hydrogen in the large intestine. Gastroenterology. 1992; 102(4 Pt 1): 1269-1277.
48. Spiller RC, Brown ML, Phillips SF: Emptying of the terminal ileum in intact humans. Influence of meal residue and ileal motility. Gastroenterology. 1987; 92(3): 724-729.
49. Zhao J, Zheng X, Chu H, et al.: A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic orocecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. Neurogastroenterol Motil. 2014; 26(6): 794-802.
50. Lupascu A, Gabrielli M, Lauritano EC, et al.: Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005; 22(11-12): 1157-1160.
51. Spiller RC: Potential biomarkers. Gastroenterol Clin North Am. In: Chey WD, editor. Irritable bowel syndrome. 40 ed. Elsevier; 2011; 40(1): 121-139.
52. Klooker TK, Braak B, Koopman KE, et al.: The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010; 59(9): 1213-1221.
53. Krawczyk M, Wolska M, Schwartz S, et al.: Concordance of genetic and breath tests for lactose intolerance in a tertiary referral centre. J Gastrointestin Liver Dis. 2008; 17(2): 135-139.
54. Lavö B, Stenstam M, Nielsen AL: Loperamide in treatment of irritable bowel syndrome-a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987; 130: 77-80.
55. Efskind PS, Bernklev T, Vatn MH: A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996; 31(5): 463-468.
56. Dove LS, Lembo A, Randall CW, et al.: Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology. 2013; 145(2): 329-338.e1.
57. Andresen V, Montori VM, Keller J, et al.: Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and metaanalysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008; 6(5): 545-555.
58. Lembo AJ, Olden KW, Ameen VZ, et al.: Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol. 2004; 2(8): 675-682.
59. Cremonini F, Nicandro JP, Atkinson V, et al.: Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012; 36(5): 437-448.
60. Chang L, Chey WD, Harris L, et al.: Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol. 2006; 101(5): 1069-1079.
61. Chang L, Tong K, Ameen V: Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol. 2010; 105(4): 866-875.
62. Chiba T, Yamamoto K, Sato S: Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2013; 6: 123-128.
63. Matsueda K, Harasawa S, Hongo M, et al.: A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 2008; 43(10): 1202-1211.
64. Fukudo S, Kinoshita Y, Okumura T, et al.: Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women. Gastroenterology. 2016; 150(2): 358-366.e8.
65. Drossman DA, Chey WD, Johanson JF, et al.: Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009; 29(3): 329-341.
66. Chey WD, Drossman DA, Johanson JF, et al.: Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2012; 35(5): 587-599.
67. Chey WD, Lembo AJ, Lavins BJ, et al.: Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebocontrolled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012; 107(11): 1702-1712.
68. Lembo AJ, Schneier HA, Shiff SJ, et al.: Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011; 365(6): 527-536.
69. Rivkin A, Chagan L: Lubiprostone: chloride channel activator for chronic constipation. Clin Ther. 2006; 28(12): 2008-2021.
70. Whitehead WE, Palsson OS, Gangarosa L, et al.: Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2011; 23(10): 944-e400.
71. Camilleri M, Bharucha AE, Ueno R, et al.: Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006; 290(5): G942-G947.
72. Busby RW, Kessler MM, Bartolini WP, et al.: Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013; 344(1): 196-206.
73. Rao S, Lembo AJ, Shiff SJ, et al.: A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012; 107(11): 1714-1724; quiz p.1725